PTC/SB/08s (08-03.)
Approved for use through 07/31/2006, OMB 0651-0231
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Pepervook Reduction Act of 1995, no persons se requested to respond to a collection of information unless of contains a valid CMB control number.

Application Number

Filing Date

INFORMATION DISCLOSURE

OTATEMENT DV ADDLIGANT					First Named Inventor   DOCHDERGER, Dellid							
STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)				Art Ur	Art Unit							
( Not for submission under 37 CFR 1.99)					Examiner Name							_
					Attorney Docket Number			BECKER-1017 US				
					U.S.	PATENTS				Remove		
Examiner Initial*	Cite No	Patent Number Kind Code <sup>1</sup>		Issue [	Name of Patentee or Applicant of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1	3060040		1962-1	0-23	Bristow						
	2	2045494		1936-0	6-23	Riddle						
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	lease click	the A	dd button.		Add		
•			U.S.P	ATENT	APPLI	CATION P	UBLI	CATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ation	of sited Document			Releva	eges,Columns,Lines where elevant Passages or Relevant gures Appear		
	1											
If you wis	h to a	l dd additional U.S. Publ	ished Ac	plication	n citatio	l n informati	on ple	ase click the Ad	d button	Add		_
				-		ENT DOC	_			Remove		_
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i		Kind Code <sup>4</sup>	Publication Date	on /	Name of Patentee or Applicant of cited Document		where Rel	or Relevant	T6
	1	0 122 572	EΡ		A2	1984-10-2	14	W.R. Grace & Co.				
	2	48 034809	JP		В	1973-01-0		Narumi Ceramics I	MFG			

	Application Number			
NEODMATION DIOCE COURT	Filing Date			
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	BUC	CHBERGER, Bernd	
Not for submission under 37 CFR 1.99)	Art Unit			
,	Examiner Name			
	Attornou Docket Numb	or	DECKED 1017 HR	

If you wish	h to a	dd add	ditional Foreign Patent Document citation information please click the Add but	ton Add			
			NON-PATENT LITERATURE DOCUMENTS	Remove			
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						
	1		VRAH, M. F. M., "Effect of Cr2O3 on sinterability and properties of mullite-spinel compo NSACTIONS INST. MATTER UK, VOL. 102, no. 3, June 2003, pages 114-118	sites", BRITISH CE	RAMIC		
If you wish to add additional non-patent literature document citation information please click the Add button Add							
			EXAMINER SIGNATURE				
Examiner Signature Date Considered							

<sup>1</sup> See Kind Codes of USPTO Patient Documents at <a href="https://www.USPTO.GDV">www.USPTO.GDV</a> or MPEP 901.84. <sup>2</sup> Enter office that issued the document, by the levi-either code (WIPO-Standard 67.3). <sup>3</sup> Par Jupanese patient documents, his enclusion of the year of the region of the region of the serial number of the patient document. Proposed that the patient document will be a controlled to the counter transfer of the patient document. The patient document will be discussed 57.4 degrees to a place a cross not an exclusion of a standard or the patient document will be discussed 57.4 degrees to a place a cross not make the patient document will be discussed 57.4 degrees to a place a cross not make the patient document will be discussed 57.4 degrees the patient document will be discuss

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# Application Number Filing Date Filing Date

### CERTIFICATION STATEMENT

Please see 37	7 CFR 1.97 and	1.98 to make the	appropriate selection(s):
---------------	----------------	------------------	---------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eVI).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

om or the signature.						
Signature	/Christopher L. Parmelee/	Date (YYYY-MM-DD)	2006-07-27			
Name/Print	Christopher L. Parmelee	Registration Number	42.980			

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S.231.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.